Risk was apparent in acute coronary syndrome trials, but did not achieve significance in elective trials.
← all excerpts
Critical Appraisal of Bivalirudin versus Heparin for Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Trials.
1
—
—